

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

SUPPLEMENTAL AGREEMENT FOR THE DISCLOSEABLE TRANSACTION IN RELATION TO CAPITAL CONTRIBUTION IN AND ACQUISITION OF 100% EQUITY INTEREST IN FENGSHUO BIO MEDICAL TECH AND 51% EQUITY INTEREST IN GUANGDONG KELV BIO MEDICAL TECH COMPANY LIMITED AND CAPITAL CONTRIBUTION TO OBTAIN 28% EQUITY INTEREST IN FENGYUAN HUAKE BIO TECH

Reference is made to the announcements dated 23 November 2015 (the “**2015 Announcement**”), 28 March 2018 (the “**March 2018 Announcement**”), 6 September 2018 and 6 November 2018 of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the 2015 Announcement.

On 30 November 2018 (after trading hours), the Purchaser, the Vendor, Mr. Zhao, the Target Company No. 1 and Fengshuo Bio Medical Tech entered into a supplemental agreement (the “**Supplemental Agreement**”) to supplement the terms of the Agreement and it was agreed as follows:

1. the net profit after taxation of Target Company No. 1 for the year ended 31 December 2017 has been audited and the 2017 Actual Profit of the Target Company No. 1 is RMB17.68 million, which failed to achieve the Guarantee Profit of RMB38 million. The Vendor has agreed to compensate the Purchaser in the amount of RMB5.69 million;

2. Target Company No. 1 has undertaken the following:

- its audited net profit for the years ending 31 December 2018 (the “**2018 Guarantee Net Profit**”) and 31 December 2019 (the “**2019 Guarantee Net Profit**”) (each a “**Guarantee Net Profit**”) will not be less than RMB20 million. Mr. Zhao and the Vendor agreed that, in the event that the 2018 Guarantee Net Profit or the 2019 Guarantee Net Profit are not achieved, the Vendor shall transfer a percentage of the equity interest in Target Company No. 1 (“**X**”) held by the Vendor to the Purchaser at no further consideration, based on the following formula:

$$X = 28\% \times (2000/\text{Guarantee Net Profit} - 1) \times 100$$

Note: The Guarantee Net Profit shall be taken as (i) RMB20 million, where it is more than RMB20 million, and (ii) RMB11.32 million, where it is less than RMB11.32 million.

- its target revenue for the year ending 31 December 2020 (the “**2020 Target Revenue**”) will be RMB38 million. Mr. Zhao and the Vendor agreed that, in the event that the 2020 Target Revenue is not achieved, the Vendor shall transfer a percentage of the equity interest in Target Company No. 1 (“**Y**”) to the Purchaser based on the following formula:

$$Y = 28\% \times (3800/2020 \text{ Target Revenue} - 1) \times 100$$

Note: The 2020 Target Revenue shall be taken as (i) RMB38 million, where it is more than RMB38 million, and (ii) RMB11.32 million, where it is less than RMB11.32 million.

3. the Purchaser retains the right to enforce the performance obligations under the Agreement and the Vendor and Mr. Zhao shall cooperate unconditionally. In the event that Target Company No. 1 is able to achieve the 2018 Guarantee Net Profit, the 2019 Guarantee Net Profit and the 2020 Target Revenue, the Purchaser shall not request for further transfer of equity interest from the Vendor.

Save for the amendments contained in the Supplemental Agreement as stated above, all other major terms and conditions of the Agreement shall remain in full force and effect.

By Order of the Board of
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 30 November 2018

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Hou Kai Wen and Mr. Lin Jiang as non-executive Directors; and Mr. Lam Chi Wing, Mr. Mai Yang Guang, and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.